We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
BioLineRx Receives Notice of Allowance for US Patent on BL-7010
News

BioLineRx Receives Notice of Allowance for US Patent on BL-7010

BioLineRx Receives Notice of Allowance for US Patent on BL-7010
News

BioLineRx Receives Notice of Allowance for US Patent on BL-7010

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "BioLineRx Receives Notice of Allowance for US Patent on BL-7010"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

BioLineRx Ltd. has announced receipt of a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for a patent claiming the use of BL-7010, a novel polymer in preventing or decreasing gluten’s deleterious effects on the gastrointestinal mucosa.

This patent, when issued, will be valid until at least 2026. Additional patents claiming the BL-7010 composition and uses thereof are granted or pending in the US, Europe, Japan, Canada, Israel, India, China, Brazil, Russia, Australia, South Africa and Hong Kong.

“We are very pleased to receive this Notice of Allowance for the BL-7010 patent in the prevention of gluten toxicity, which significantly broadens our coverage in the United States,” stated Dr. Kinneret Savitsky, Chief Executive Officer of BioLineRx.

Dr. Savitsky continued, “We recently announced unblinded results of a Phase 1/2 safety study for BL-7010, in which the compound was shown to have no systemic exposure. This is of significance since it may support classification of BL-7010 as a medical device in Europe, accelerating its pathway to commercialization. We are currently in the final stages of the Phase 1/2 safety study in order to select the optimal dose of BL-7010 for the upcoming efficacy study, which we look forward to commencing early next year.”

Advertisement